Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
mTOR inhibitors: A novel class of anti-cancer agents.
Riaz H, Riaz T, Hussain SA.
Infect Agent Cancer. 2012 Jan 3;7(1):1. No abstract available.
Related citations
Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.
Rao RD, Buckner JC, Sarkaria JN.
Curr Cancer Drug Targets. 2004 Dec;4(8):621-35. Review.
The impact of mTOR inhibitors on the development of malignancy.
Geissler EK.
Transplant Proc. 2008 Dec;40(10 Suppl):S32-5.
Therapeutic targets: MTOR and related pathways.
Dancey JE.
Cancer Biol Ther. 2006 Sep;5(9):1065-73. Epub 2006 Sep 6. Review.
Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.
Morgan TM, Koreckij TD, Corey E.
Curr Cancer Drug Targets. 2009 Mar;9(2):237-49. Review.
Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H.
J Heart Lung Transplant. 2007 Jun;26(6):557-64.
mTOR signaling and drug development in cancer.
Dancey J.
Nat Rev Clin Oncol. 2010 Apr;7(4):209-19. Epub 2010 Mar 16. Review.
[Use of mTOR-inhibitors in solid tumors].
Seidel C, Grünwald V.
Med Monatsschr Pharm. 2011 Apr;34(4):116-26; quiz 127-8. Review. German.
Dissecting the role of mTOR: lessons from mTOR inhibitors.
Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N.
Biochim Biophys Acta. 2010 Mar;1804(3):433-9. Epub 2009 Dec 11. Review.
The mTOR pathway: a new target in cancer therapy.
Ciuffreda L, Di Sanza C, Incani UC, Milella M.
Curr Cancer Drug Targets. 2010 Aug;10(5):484-95. Review.
Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Baselga J.
Oncologist. 2011;16 Suppl 1:12-9. Review.
Current development of mTOR inhibitors as anticancer agents.
Faivre S, Kroemer G, Raymond E.
Nat Rev Drug Discov. 2006 Aug;5(8):671-88.
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
Yuan R, Kay A, Berg WJ, Lebwohl D.
J Hematol Oncol. 2009 Oct 27;2:45. Review.
Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.
Ghayad SE, Cohen PA.
Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):29-57. Review.
The mTOR protein as a target in thyroid cancer.
Souza EC, Ferreira AC, Carvalho DP.
Expert Opin Ther Targets. 2011 Sep;15(9):1099-112. doi: 10.1517/14728222.2011.594044. Epub 2011 Jun 25. Review.
The multiple facets of mTOR in immunity.
Weichhart T, Säemann MD.
Trends Immunol. 2009 May;30(5):218-26. Epub 2009 Apr 8. Review.
[PI3K-AKT-mTOR pathway inhibitors].
Cortot A, Armand JP, Soria JC.
Bull Cancer. 2006 Jan;93(1):19-26. Review. French.
Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Bjelogrlić SK, Srdić T, Radulović S.
J BUON. 2006 Jul-Sep;11(3):267-76. Review.
The rationale for mTOR inhibition in epithelial ovarian cancer.
Trinh XB, van Dam PA, Dirix LY, Vermeulen PB, Tjalma WA.
Expert Opin Investig Drugs. 2009 Dec;18(12):1885-91. Review.
mTOR inhibitors in advanced renal cell carcinoma.
Voss MH, Molina AM, Motzer RJ.
Hematol Oncol Clin North Am. 2011 Aug;25(4):835-52. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on